Welcome to our dedicated page for Cadrenal Therape SEC filings (Ticker: CVKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including Current Reports on Form 8-K, proxy materials, and other documents filed with the Securities and Exchange Commission. As an emerging growth biopharmaceutical company focused on anticoagulant therapies, Cadrenal uses these filings to report material events, governance matters, and financing activities that shape its clinical and corporate trajectory.
Investors researching CVKD can use this page to review Form 8-K filings that describe offerings of common stock and warrants, at-the-market equity programs, and other capital-raising transactions. Additional 8-K reports furnish quarterly financial results, including research and development spending and general and administrative expenses, which help illustrate how resources are being allocated to programs such as tecarfarin, frunexian, and VLX-1005.
The company’s definitive proxy statement on Schedule 14A offers detail on board composition, annual meeting proposals, and governance practices. Over time, annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide broader context on risk factors, clinical development plans, and the status of regulatory designations for Cadrenal’s anticoagulation pipeline.
Stock Titan enhances this document set with AI-powered summaries that explain the key points of lengthy filings in plain language. Users can quickly understand the implications of a new financing, changes in capital structure, or updates to clinical strategy without reading every page. The platform also surfaces insider and beneficial ownership information when disclosed, helping users see how management and major holders are aligned with the company’s progress. With real-time updates from EDGAR and AI-generated insights, this page is designed to make Cadrenal’s regulatory record more accessible and easier to interpret.
Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 notifying the proposed sale of 107 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $1517.26. The planned sale is listed for 10/06/2025 and the shares were originally acquired as founders' shares on 05/17/2022.
The filing also lists multiple recent Rule 10b5-1 sales by the same person between 08/27/2025 and 10/01/2025, totaling substantial share volumes (for example 10,900 shares on 09/25/2025). The filer certifies no undisclosed material adverse information and indicates reliance on a trading plan where applicable.
Cadrenal Therapeutics, Inc. (CVKD) director, CEO and chairman Quang Pham reported a planned sale of 500 shares of common stock executed on 10/02/2025 under a Rule 10b5-1 trading arrangement at prices ranging from $14.04 to $14.27, with a weighted average price of $14.13. Following the transaction, Mr. Pham directly owns 202,133 shares and indirectly holds 200,000 shares through The PVBQ Living Trust, for which he is trustee and retains sole voting and dispositive power. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Cadrenal Therapeutics (CVKD) Form 144 notifies the SEC of a proposed sale of 500 common shares to be executed on or about 10/02/2025 through Merrill Lynch (Ponte Vedra Beach, FL) on the NASDAQ. The filing identifies Quang X. Pham as the seller and shows those 500 shares were originally acquired as Founders Shares on 01/25/2022. The filing also discloses a series of sales by the same person over the prior three months: 3,836 shares on 08/27/2025, 1,193 on 08/28/2025, 2,581 on 09/24/2025, 6,790 on 09/25/2025, 419 on 09/29/2025, and 881 on 10/01/2025, with gross proceeds listed for each sale. The filer certifies compliance with Rule 144 representations required by the form.
Cadrenal Therapeutics insider Form 4 summary: Director, CEO and Chairman Quang Pham reported pre-arranged sales of common stock under a Rule 10b5-1 trading plan. On 09/29/2025 he sold 419 shares at a weighted average price of $14.01, and on 10/01/2025 he sold 881 shares at a weighted average price of $14.01. Following these transactions Mr. Pham directly beneficially owned 202,633 shares. He also has indirect beneficial ownership of 200,000 shares through The PVBQ Living Trust, for which he is trustee and retains sole voting and dispositive power.
Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 reporting a proposed sale of 881 common shares through Merrill Lynch (address listed) with an approximate aggregate market value of $12,343.19 and an approximate sale date of 10/01/2025 on NASDAQ. The filing states these shares were acquired as Founders Shares on 01/25/2022 from the issuer and payment was recorded on the acquisition date. The notice also lists prior open-market sales by Quang X. Pham during the past three months totaling 14,819 shares on multiple dates between 08/27/2025 and 09/29/2025 with aggregate gross proceeds reported in the filing. The filer represents no undisclosed material adverse information and includes the standard Rule 144/10b5-1 attestations.
Cadrenal Therapeutics, Inc. (CVKD) notice reports a proposed sale of 1,700 common shares, with an aggregate market value of $23,511, representing part of 2,046,854 shares outstanding. The sale is scheduled approximately for 10/01/2025 and the broker listed is Morgan Stanley Smith Barney LLC.
The shares to be sold were acquired as Founders Shares on 05/17/2022. Over the past three months the filer completed 5 sales totaling 14,500 shares for aggregate gross proceeds of $203,567.01 under 10b5-1 plans on dates between 08/27/2025 and 09/29/2025. The filer certifies no undisclosed material adverse information.
Cadrenal Therapeutics (CVKD) Form 144 notice: An insider proposes a Rule 144 sale of 419 common shares through Merrill Lynch with an aggregate market value of $5,869.50, planned for 09/29/2025. The shares were acquired as founders shares on 01/25/2022. The filing reports 2,046,854 shares outstanding for the issuer. The filer previously sold common stock in the past three months on 08/27/2025, 08/28/2025, 09/24/2025 and 09/25/2025 totaling 14,400 shares for $201,765.14 in gross proceeds. The notice includes the required signature attesting no undisclosed material information.
Cadrenal Therapeutics (CVKD) filed a Form 144 notifying a proposed sale of 100 common shares through Morgan Stanley Smith Barney with an aggregate market value of $1,403, scheduled approximately for 09/29/2025. The filing reports total shares outstanding of 2,046,854, and shows the 100 shares were acquired as founders shares on 05/17/2022. The filer represents compliance with Rule 144 and states no undisclosed material adverse information. The filing also lists recent Rule 10b5-1 sales by Matthew Szot totaling 14,400 shares between 08/27/2025 and 09/25/2025 for gross proceeds of $179,166.01.
Cadrenal Therapeutics, Inc. (CVKD) filing is a Form 144/A notice reporting a proposed sale of 6,790 common shares through Merrill Lynch (Ponte Vedra Beach, FL) with an approximate aggregate market value of $95,661.94, and an approximate sale date of 09/25/2025 on NASDAQ. The shares were acquired as Founders Shares on 01/25/2022. The filing also discloses three insider sales in the past three months by Quang X. Pham totaling 7,610 shares for gross proceeds of $106,104.20 across sales on 08/27/2025, 08/28/2025, and 09/24/2025. The notice includes the required certification that the seller is not aware of undisclosed material adverse information.
Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, Inc. (CVKD), reported sales of company common stock on two dates. On 09/24/2025 he sold 1,500 shares at a weighted average price of $13.9953, and on 09/25/2025 he sold 10,900 shares at a weighted average price of $14.0534, for a total of 12,400 shares sold. After these transactions the reporting person beneficially owned 18,933 shares, down from 29,833 shares following the first sale. The Form 4 is signed by the reporting person on 09/26/2025 and includes explanatory notes that the reported sales occurred in multiple transactions within the stated price ranges.